MEDI-1912 is a human monoclonal antibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through TrkA and p75 receptors. MEDI-1912 can be used in chronic pain research[1].
Target:
Neurokinin Receptor,Trk Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
